Display Settings:

Format

Send to:

Choose Destination

46,XX Testicular Disorder of Sex Development.

Authors

Vilain EJ.

Source

GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
2003 Oct 30 [updated 2009 May 26].

Excerpt

DISEASE CHARACTERISTICS:

46,XX testicular disorder of sex development (46,XX testicular DSD) is characterized by the presence of a 46,XX karyotype; male external genitalia ranging from normal to ambiguous; two testicles; azoospermia; and absence of Müllerian structures. Approximately 80% of individuals with 46,XX testicular DSD present after puberty with normal pubic hair and normal penile size, but small testes, gynecomastia, and sterility resulting from azoospermia. Approximately 20% of individuals with 46,XX testicular DSD present at birth with ambiguous genitalia. Gender role and gender identity are reported as male. If untreated, males with 46,XX testicular DSD experience the consequences of testosterone deficiency.

DIAGNOSIS/TESTING:

Diagnosis of 46,XX testicular DSD is based on the combination of clinical findings, endocrine testing, and cytogenetic testing. Endocrine studies usually show hypergonadotropic hypogonadism secondary to testicular failure. Cytogenetic studies at the 550 band level demonstrate a 46,XX karyotype. SRY, the gene that encodes the sex-determining region Y protein, is the only gene known to be associated with 46,XX testicular DSD; at least one more as-yet-unknown gene at another locus is implicated. Approximately 80% of individuals with the 46,XX testicular DSD are SRY positive as shown by use of FISH or PCR amplification of SRY; approximately 20% of individuals with 46,XX testicular DSD are SRY negative.

MANAGEMENT:

Treatment of manifestations: Similar to that for other causes of testosterone deficiency. After age 14 years, low-dose testosterone therapy is initiated and gradually increased to reach adult levels. In affected individuals with short stature who are eligible for growth hormone therapy, testosterone therapy is either delayed or given at lower doses initially in order to maximize the growth potential. Reduction mammoplasty may need to be considered if gynecomastia remains an issue following testosterone replacement therapy. Treatment for osteopenia is by standard protocols. Surveillance: Monitor for testosterone effects during testosterone replacement therapy, including prostate size and prostate-specific antigen (PSA) in adults; bone mineral density determination by bone densitometry (DEXA) annually, if osteopenia has been diagnosed. Agents/circumstances to avoid: Contraindications to testosterone replacement therapy include prostate cancer (known or suspected) and breast cancer; oral androgens such as methyltestosterone and fluoxymesterone should not be given because of liver toxicity.

GENETIC COUNSELING:

SRY-positive 46,XX testicular DSD is generally not inherited because it results from de novo abnormal interchange between the Y chromosome and the X chromosome, resulting in the presence of the gene SRY on the X chromosome and infertility. When SRY is translocated to another chromosome or when fertility is preserved, sex-limited autosomal dominant inheritance is observed. The mode of inheritance of SRY-negative 46,XX testicular DSD is not known, but autosomal recessive inheritance has been postulated. Prenatal diagnosis for pregnancies at risk for SRY-positive 46,XX testicular DSD is possible.

Copyright © 1993-2014, University of Washington, Seattle. All rights reserved.

PMID:
20301589
[PubMed]
Books & DocumentsFree full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Write to the Help Desk